Phase 2 dose expansion of START-001: A phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy ...
World first study of novel antibody therapeutic in peanut allergic individuals using the proprietary SEQ SIFTER™ antibody discovery platform now fully enrolled SOUTH SAN FRANCISCO, Calif.--(BUSINESS ...
Scientific progress rarely moves in straight lines and often takes unexpected twists and turns. This pattern has defined Renascience’s journey, which began some 25 years ago with an effort to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results